Index RUT P/E - EPS (ttm) -2.16 Insider Own 54.38% Shs Outstand 41.13M Perf Week 9.01%
Market Cap 708.22M Forward P/E - EPS next Y -3.17 Insider Trans 2.12% Shs Float 22.64M Perf Month 11.14%
Income -90.80M PEG - EPS next Q -0.69 Inst Own 37.37% Short Float 4.48% Perf Quarter 1.71%
Sales 0.00M P/S - EPS this Y -45.64% Inst Trans - Short Ratio 6.41 Perf Half Y 63.09%
Book/sh 6.61 P/B 2.16 EPS next Y -9.30% ROA -27.78% Short Interest 1.01M Perf Year -14.76%
Cash/sh 6.82 P/C 2.09 EPS next 5Y - ROE -29.11% 52W Range 5.85 - 17.70 Perf YTD 65.93%
Dividend Est. - P/FCF - EPS past 5Y - ROI -27.68% 52W High -19.38% Beta 2.17
Dividend TTM - Quick Ratio 18.06 Sales past 5Y 0.00% Gross Margin - 52W Low 143.93% ATR (14) 0.77
Dividend Ex-Date - Current Ratio 18.06 EPS Y/Y TTM - Oper. Margin 0.00% RSI (14) 63.95 Volatility 7.16% 5.88%
Employees 28 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 33.50
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -127.38% Payout - Rel Volume 1.18 Prev Close 14.65
Sales Surprise - EPS Surprise -4.79% Sales Q/Q - Earnings May 09 BMO Avg Volume 158.14K Price 14.27
SMA20 15.34% SMA50 9.98% SMA200 30.29% Trades
Volume 189,561 Change -2.59%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-02-24 Initiated Goldman
Buy
$30
Mar-07-23 Initiated Wells Fargo
Overweight
$27
Mar-07-23 Initiated Stifel
Buy
$45
Mar-07-23 Initiated Guggenheim
Buy
$32
Mar-07-23 Initiated Evercore ISI
Outperform
Mar-07-23 Initiated Credit Suisse
Outperform
$40
Mar-07-23 Initiated BofA Securities
Buy
$39
May-09-24 11:56AM
07:00AM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-05-24 12:16AM
10:51AM
Loading…
Mar-22-24 10:51AM
Mar-21-24 11:53AM
09:11AM
07:00AM
Mar-13-24 04:05PM
Feb-08-24 08:00AM
Jan-29-24 04:05PM
Jan-17-24 12:00PM
Jan-04-24 04:05PM
Dec-21-23 04:05PM
09:22AM
Loading…
Nov-12-23 09:22AM
Nov-11-23 11:30AM
Nov-09-23 04:05PM
Nov-07-23 05:12PM
04:05PM
Nov-02-23 10:00AM
Oct-31-23 04:05PM
Oct-13-23 04:10PM
Sep-19-23 04:00PM
Sep-14-23 04:05PM
Sep-11-23 04:05PM
Sep-10-23 07:47AM
07:45AM
Sep-09-23 05:00AM
Sep-05-23 04:05PM
09:55AM
Loading…
09:55AM
Aug-29-23 04:05PM
Aug-22-23 05:45PM
Aug-07-23 04:05PM
Jul-31-23 04:05PM
Jul-17-23 04:01PM
Jun-09-23 08:04AM
May-31-23 08:00AM
May-15-23 04:01PM
May-10-23 08:39AM
May-02-23 08:00AM
May-01-23 08:00AM
Apr-27-23 04:47PM
Mar-15-23 04:01PM
Mar-04-23 04:30PM
Mar-01-23 04:05PM
Feb-20-23 08:00AM
Feb-17-23 12:08PM
(American City Business Journals)
Feb-14-23 04:01PM
Feb-10-23 05:16PM
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rodman David Malcom Chief Medical Officer Apr 12 '24 Option Exercise 1.08 6,349 6,857 66,997 Apr 15 04:24 PM Rodman David Malcom Chief Medical Officer Apr 11 '24 Option Exercise 0.54 5,017 2,709 60,648 Apr 15 04:24 PM Rodman David Malcom Chief Medical Officer Mar 12 '24 Option Exercise 1.08 6,348 6,856 55,631 Mar 13 05:35 PM Rodman David Malcom Chief Medical Officer Mar 11 '24 Option Exercise 0.54 5,017 2,709 49,283 Mar 13 05:35 PM Rodman David Malcom Chief Medical Officer Feb 12 '24 Option Exercise 0.84 11,366 9,566 44,266 Feb 13 04:08 PM Samsara BioCapital GP, LLC 10% Owner Feb 12 '24 Buy 13.50 555,555 7,499,992 5,074,916 Feb 14 09:06 PM Rodman David Malcom Chief Medical Officer Jan 12 '24 Option Exercise 1.08 6,348 6,856 32,900 Jan 12 04:01 PM Rodman David Malcom Chief Medical Officer Jan 11 '24 Option Exercise 0.54 5,017 2,709 26,552 Jan 12 04:01 PM Rodman David Malcom Chief Medical Officer Dec 11 '23 Option Exercise 0.54 5,018 2,710 20,069 Dec 12 05:08 PM Congleton Jon Chief Executive Officer Nov 22 '23 Buy 5.97 4,250 25,356 1,049,068 Nov 27 04:01 PM Rodman David Malcom Chief Medical Officer Nov 13 '23 Option Exercise 0.54 5,017 2,709 15,051 Nov 14 06:18 PM Rodman David Malcom Chief Medical Officer Nov 03 '23 Option Exercise 0.54 10,034 5,418 10,034 Nov 07 05:15 PM Congleton Jon Chief Executive Officer Sep 06 '23 Buy 12.08 2,250 27,180 1,044,818 Sep 08 08:49 AM Congleton Jon Chief Executive Officer Aug 17 '23 Buy 12.10 2,250 27,225 1,042,568 Aug 21 04:03 PM Rodman David Malcom Chief Medical Officer Aug 11 '23 Option Exercise 0.80 157,091 125,967 80,909 Aug 11 07:11 PM Congleton Jon Chief Executive Officer Aug 11 '23 Buy 12.89 2,000 25,780 1,040,318 Aug 11 07:11 PM Rodman David Malcom Chief Medical Officer Aug 11 '23 Sale 12.81 157,091 2,012,336 0 Aug 11 07:11 PM Rodman David Malcom Chief Medical Officer Aug 10 '23 Option Exercise 0.54 74,625 40,298 74,625 Aug 11 07:11 PM Rodman David Malcom Chief Medical Officer Aug 10 '23 Sale 13.16 74,625 982,065 0 Aug 11 07:11 PM
Index RUT P/E - EPS (ttm) - Insider Own 34.64% Shs Outstand 41.21M Perf Week -9.35%
Market Cap 748.03M Forward P/E - EPS next Y -4.84 Insider Trans 24.31% Shs Float 25.73M Perf Month -9.57%
Income - PEG - EPS next Q -1.05 Inst Own 67.75% Short Float 14.00% Perf Quarter -19.39%
Sales - P/S - EPS this Y 66.73% Inst Trans - Short Ratio 11.55 Perf Half Y -
Book/sh 9.84 P/B 1.93 EPS next Y 11.91% ROA - Short Interest 3.60M Perf Year -
Cash/sh 10.31 P/C 1.84 EPS next 5Y - ROE - 52W Range 13.14 - 33.92 Perf YTD -17.93%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -43.99% Beta -
Dividend TTM - Quick Ratio 19.35 Sales past 5Y 0.00% Gross Margin - 52W Low 44.60% ATR (14) 1.46
Dividend Ex-Date - Current Ratio 19.35 EPS Y/Y TTM - Oper. Margin - RSI (14) 39.92 Volatility 7.74% 6.33%
Employees - Debt/Eq 0.07 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 31.00
Option/Short No / Yes LT Debt/Eq 0.06 EPS Q/Q - Payout - Rel Volume 0.78 Prev Close 20.38
Sales Surprise - EPS Surprise 8.10% Sales Q/Q - Earnings Mar 21 AMC Avg Volume 312.09K Price 19.00
SMA20 -3.65% SMA50 -17.77% SMA200 -9.83% Trades
Volume 242,392 Change -6.77%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-05-23 Initiated Truist
Buy
$34
Dec-05-23 Initiated TD Cowen
Outperform
Dec-05-23 Initiated JP Morgan
Overweight
$23
Dec-05-23 Initiated Jefferies
Buy
$28
Apr-15-24 04:05PM
Mar-21-24 10:53PM
04:05PM
Feb-29-24 04:01PM
Jan-03-24 08:05AM
04:04PM
Loading…
Dec-18-23 04:04PM
Dec-13-23 10:51PM
04:05PM
Dec-11-23 07:53PM
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Third Rock Ventures V, L.P. 10% Owner Nov 14 '23 Buy 15.00 1,333,333 19,999,995 1,807,119 Nov 14 07:08 PM PERCEPTIVE ADVISORS LLC Former 10% Owner Nov 14 '23 Buy 15.00 666,666 9,999,990 2,912,835 Nov 14 04:32 PM Samsara BioCapital GP, LLC 10% Owner Nov 14 '23 Buy 15.00 666,666 9,999,990 4,121,689 Nov 16 07:39 PM
Index RUT P/E - EPS (ttm) -2.20 Insider Own 23.20% Shs Outstand 75.98M Perf Week -3.64%
Market Cap 1.16B Forward P/E - EPS next Y -2.01 Insider Trans -0.56% Shs Float 61.25M Perf Month 3.78%
Income -183.26M PEG - EPS next Q -0.56 Inst Own 87.20% Short Float 21.85% Perf Quarter -7.38%
Sales 0.00M P/S - EPS this Y -11.89% Inst Trans -2.45% Short Ratio 16.00 Perf Half Y 17.81%
Book/sh 2.29 P/B 6.35 EPS next Y 9.69% ROA -62.98% Short Interest 13.38M Perf Year 70.98%
Cash/sh 2.99 P/C 4.87 EPS next 5Y - ROE -89.09% 52W Range 5.56 - 21.17 Perf YTD -22.61%
Dividend Est. - P/FCF - EPS past 5Y 8.79% ROI -79.76% 52W High -31.27% Beta 0.89
Dividend TTM - Quick Ratio 6.58 Sales past 5Y -5.25% Gross Margin - 52W Low 161.69% ATR (14) 0.87
Dividend Ex-Date - Current Ratio 6.58 EPS Y/Y TTM 23.04% Oper. Margin 0.00% RSI (14) 48.26 Volatility 6.07% 5.75%
Employees 150 Debt/Eq 0.33 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.00 Target Price 26.25
Option/Short Yes / Yes LT Debt/Eq 0.26 EPS Q/Q -19.87% Payout - Rel Volume 0.74 Prev Close 14.50
Sales Surprise - EPS Surprise -22.10% Sales Q/Q - Earnings May 07 BMO Avg Volume 836.53K Price 14.55
SMA20 1.38% SMA50 -3.84% SMA200 18.02% Trades
Volume 620,396 Change 0.34%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated Raymond James
Strong Buy
$30
Oct-25-23 Upgrade Jefferies
Hold → Buy
$20
Apr-03-23 Resumed Piper Sandler
Overweight
$26
Sep-19-22 Resumed H.C. Wainwright
Buy
$30
Jul-12-22 Initiated Truist
Buy
$20
Mar-23-22 Initiated H.C. Wainwright
Buy
$24
Dec-22-21 Downgrade Jefferies
Buy → Hold
$52 → $28
Nov-19-21 Initiated Piper Sandler
Overweight
$56
Apr-26-21 Resumed Credit Suisse
Outperform
$65
Jan-11-21 Initiated Credit Suisse
Outperform
$65
Jan-06-21 Initiated JP Morgan
Overweight
$59
Mar-12-20 Initiated Robert W. Baird
Outperform
$35
Show Previous Ratings
May-07-24 01:53PM
10:19AM
08:52AM
07:00AM
Apr-24-24 06:33AM
04:15PM
Loading…
Apr-12-24 04:15PM
Mar-20-24 05:31AM
Mar-19-24 10:52PM
07:00AM
Mar-15-24 04:15PM
08:18AM
Feb-28-24 08:00AM
Feb-16-24 04:15PM
Feb-15-24 08:00AM
Feb-06-24 08:00AM
08:00AM
Loading…
Jan-25-24 08:00AM
Jan-23-24 08:00AM
Jan-22-24 07:00AM
(The Wall Street Journal)
Jan-18-24 05:01PM
Jan-12-24 04:15PM
Jan-04-24 08:00AM
Jan-02-24 01:57PM
Dec-30-23 07:01PM
Dec-19-23 08:00AM
Dec-15-23 04:15PM
Dec-10-23 09:05AM
Nov-17-23 04:15PM
Nov-12-23 12:32PM
Nov-07-23 08:14AM
07:15AM
09:55AM
Loading…
Nov-06-23 09:55AM
Nov-03-23 11:52PM
04:00PM
Nov-02-23 08:00AM
Oct-31-23 08:50AM
Oct-24-23 12:00PM
Oct-23-23 08:00AM
Oct-19-23 09:55AM
08:00AM
Oct-18-23 08:30AM
Oct-16-23 04:15PM
Oct-13-23 12:45PM
Oct-12-23 04:17PM
Oct-11-23 08:57PM
05:05PM
04:44PM
Sep-19-23 08:00AM
Sep-15-23 04:15PM
Sep-07-23 09:55AM
Aug-18-23 04:15PM
Aug-09-23 04:15PM
Aug-02-23 10:41AM
Jul-13-23 08:00AM
Jun-30-23 11:00AM
Jun-15-23 08:00AM
Jun-01-23 04:05PM
May-10-23 08:00AM
May-09-23 07:30AM
May-08-23 08:00AM
Apr-17-23 12:57PM
Apr-12-23 08:00AM
Apr-10-23 04:05PM
Mar-15-23 08:00AM
Mar-07-23 07:00AM
Mar-01-23 08:00AM
Feb-27-23 08:00AM
Feb-17-23 08:00AM
Feb-11-23 07:23AM
Feb-06-23 08:00AM
Jan-09-23 08:00AM
Jan-03-23 08:00AM
Nov-16-22 06:04AM
Nov-15-22 08:00AM
Nov-14-22 08:00AM
Nov-10-22 09:00AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-22-22 07:00AM
Oct-06-22 08:00AM
Oct-04-22 08:00AM
Sep-22-22 04:15PM
Sep-20-22 07:00AM
Sep-19-22 02:39PM
Sep-16-22 08:30AM
Sep-04-22 08:09AM
Aug-08-22 04:15PM
Jul-25-22 07:14AM
(Simply Wall St.) -10.51%
Jul-19-22 07:30AM
Jul-15-22 08:00AM
Jul-11-22 09:55AM
Jul-01-22 04:00PM
Jun-27-22 04:06PM
Jun-24-22 09:55AM
Jun-17-22 11:28AM
07:30AM
07:00AM
Jun-09-22 04:01PM
Jun-08-22 09:55AM
Jun-02-22 07:30AM
May-20-22 09:35AM
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Backstrom Jay T. CHIEF EXECUTIVE OFFICER Feb 16 '24 Sale 15.74 11,614 182,842 352,671 Feb 20 04:46 PM Myles Edward H COO & CFO Feb 16 '24 Sale 15.74 4,744 74,686 210,976 Feb 21 06:13 PM Parlavecchio Caryn CHRO Feb 16 '24 Sale 15.74 3,751 59,053 157,744 Feb 20 04:52 PM Ho Junlin GENERAL COUNSEL Feb 16 '24 Sale 15.74 3,489 54,928 208,771 Feb 20 04:48 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Feb 16 '24 Sale 15.74 2,512 39,547 147,019 Feb 20 04:58 PM Myles Edward H COO & CFO Jan 16 '24 Sale 15.93 6,634 105,670 162,150 Jan 18 04:07 PM Ho Junlin GENERAL COUNSEL Jan 16 '24 Sale 15.93 4,186 66,677 154,405 Jan 18 04:05 PM Parlavecchio Caryn CHRO Jan 16 '24 Sale 15.93 2,849 45,381 114,350 Jan 18 04:08 PM Qatanani Mo SVP AND HEAD OF RESEARCH Jan 16 '24 Sale 15.93 2,002 31,889 78,816 Jan 18 04:11 PM Myles Edward H COO & CFO Dec 29 '23 Option Exercise 4.86 12,459 60,551 181,243 Dec 29 07:13 PM Myles Edward H COO & CFO Dec 29 '23 Sale 18.83 12,459 234,633 168,784 Dec 29 07:13 PM Qatanani Mo SVP AND HEAD OF RESEARCH Dec 14 '23 Option Exercise 10.00 8,437 84,370 105,480 Dec 15 04:13 PM Qatanani Mo SVP AND HEAD OF RESEARCH Dec 14 '23 Sale 18.18 24,662 448,444 80,818 Dec 15 04:13 PM Myles Edward H COO & CFO Dec 07 '23 Option Exercise 4.86 24,914 121,082 193,698 Dec 08 04:12 PM Myles Edward H COO & CFO Dec 07 '23 Sale 17.53 24,914 436,820 168,784 Dec 08 04:12 PM Myles Edward H COO & CFO Nov 02 '23 Sale 12.51 35,007 438,039 168,784 Nov 03 06:11 PM AKKARAJU SRINIVAS Director Oct 16 '23 Buy 6.85 2,189,781 15,000,000 6,788,609 Oct 18 05:46 PM Samsara BioCapital GP, LLC 10% Owner Oct 16 '23 Buy 6.85 2,189,781 15,000,000 6,788,609 Oct 18 05:44 PM Invus Public Equities, L.P. 10% Owner Oct 12 '23 Buy 6.86 2,199,931 15,086,736 11,259,438 Oct 16 05:46 PM Qatanani Mo SVP AND HEAD OF RESEARCH Sep 18 '23 Sale 6.34 1,945 12,331 97,043 Sep 20 07:28 PM Parlavecchio Caryn CHRO Aug 16 '23 Sale 6.83 1,353 9,241 117,199 Aug 18 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
